Negative in Ames, mouse lymphoma and in vivo rat bone marrow micronucleus assays
“Avacopan was negative in all assays including the in vitro bacterial mutagenicity study (Ames test), in vitro mouse lymphoma forward-mutation assay, and in vivo rat bone marrow micronucleus study.”
✓ VerifiedFDA multi-discipline review, p. 383Source ↗
Carcinogenicity
2-year rat and hamster: no tumorigenic potential up to 100 mg/kg/day (~3x and ~6x MRHD AUC)
“Two-year carcinogenicity studies in Sprague-Dawley rats and Syrian hamsters were conducted to assess the carcinogenic potential of avacopan. Avacopan demonstrated no tumorigenic potential in a study with rats that received oral doses up to 100 mg/kg/day (approximately 3 times the MRHD in adults on an AUC basis) and a study in hamsters that received oral doses up to 100 mg/kg/day (approximately 6 times the MRHD in adults on an AUC basis).”
Hamster and rabbit EFD: no fetal harm or malformations up to 1000 and 200 mg/kg/day
“In embryofetal development studies with hamsters and rabbits, no fetal harm or malformations were observed with oral doses of CCX168 up 1000 and 200 mg/kg/day.”
✓ VerifiedFDA multi-discipline review, p. 384Source ↗
Safety pharmacology
Monkey telemetry: no blood pressure or ECG (incl. QTc) effects up to 50 mg/kg
“In the telemetry study in conscious monkeys, there were no effects on cardiovascular (blood pressure) and electrocardiographic parameters (P, PR, QRS, QT and QTc intervals, and R amplitude) following single oral doses up to 50 mg/kg, the highest dose tested.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative